Reader TTS

Access through your institution Buy or subscribe Patients with castration-resistant, metastatic prostate cancer can improve their survival time to a limited degree by treatment with

docetaxel, but the hunt is on for additional therapeutic strategies that can delay disease progression and further extend life expectancy among these individuals. A pair of recent randomized

placebo-controlled trials has shown apparent survival benefits following treatment with sipuleucel-T. This cancer vaccine is based on patient-derived peripheral blood monocytes that have

been activated by treatment with PA2024, a fusion of the tumor marker prostatic acid phosphatase with granulocyte-macrophage colony-stimulating factor. Kantoff and co-workers have now

followed up on these trials with a larger-scale, double-blinded, placebo-controlled multicenter trial, described in an article in the _New England Journal of Medicine_. This is a preview of

subscription content, access via your institution ACCESS OPTIONS Access through your institution Subscribe to this journal Receive 4 print issues and online access $259.00 per year only

$64.75 per issue Learn more Buy this article * Purchase on SpringerLink * Instant access to full article PDF Buy now Prices may be subject to local taxes which are calculated during checkout

ADDITIONAL ACCESS OPTIONS: * Log in * Learn about institutional subscriptions * Read our FAQs * Contact customer support ACKNOWLEDGEMENTS Research Highlights is sponsored by an educational

grant from AstraZeneca. RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Prostate News. _Prostate Cancer Prostatic Dis_ 13, 296–299 (2010).

https://doi.org/10.1038/pcan.2010.42 Download citation * Published: 11 November 2010 * Issue Date: December 2010 * DOI: https://doi.org/10.1038/pcan.2010.42 SHARE THIS ARTICLE Anyone you

share the following link with will be able to read this content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided by the

Springer Nature SharedIt content-sharing initiative